AZD4360

AZD4360 is an **antibody-drug conjugate (ADC)** specifically designed to target **claudin 18.2 (CLDN18.2)**, a tight junction protein highly expressed in certain gastrointestinal cancers. Developed by AstraZeneca, AZD4360 is in early-stage clinical development for the treatment of advanced and metastatic solid tumors, including gastric cancer, gastroesophageal junction cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma. The mechanism of action involves binding to CLDN18.2 on tumor cells, delivering a cytotoxic payload that induces tumor cell death. The agent is being evaluated for safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy in adult patients with CLDN18.2-positive cancers who have previously received at least one line of therapy[1][2][3][4][5][7][9][10].

Other names

AZD 4360AZD4360AZD-4360